34041-52-6

Upstream product

• 591-31-1 3-methoxy-benzaldehyde 
• 1254941-88-2 1-(3,4-dichlorophenyl)-2-((3-methoxybenzyl)(methyl)amino)ethanone 

Downstream Products

• 1255925-44-0 4-(3,4-dichlorophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl trifluoromethanesulfonate 
• 1254941-99-5 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline 
• 1254942-01-2 tert-butyl 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1255924-39-0 4-(4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)benzamide 
• 1255925-45-1 tert-butyl 4-(3,4-dichlorophenyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant academic research and scientific papers

ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF

Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF

Novel [l,2,4]triazolo[l,5-α]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SAl and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-I and N-2 are also described in the present invention.

Substituted 4-phenyl isoquinolines

4-Phenyl isoquinolines wherein the 4-phenyl ring is substituted with a halogen or nitro group and processes for their preparation are described. The end products are useful as antidepressant agents.